Walvax Biotechnology Co., Ltd.

Walvax Biotechnology provides the research and development, manufacture, and distribution of vaccines in China and globally. Its vaccine portfolio includes recombinant human papillomavirus bivalent, 13-valent pneumococcal polysaccharide conjugate, 23-valent pneumococcal polysaccharide, group ACYW135 meningococcal polysaccharide, group A and C meningococcal polysaccharide, group A and group C meningococcal conjugate, and haemophilus influenzae type b conjugate vaccines Diphtheria, tetanus and acellular pertussis combined vaccine. Founded in 2001, the company is headquartered in Kunming, China.